JP2020504138A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504138A5
JP2020504138A5 JP2019536978A JP2019536978A JP2020504138A5 JP 2020504138 A5 JP2020504138 A5 JP 2020504138A5 JP 2019536978 A JP2019536978 A JP 2019536978A JP 2019536978 A JP2019536978 A JP 2019536978A JP 2020504138 A5 JP2020504138 A5 JP 2020504138A5
Authority
JP
Japan
Prior art keywords
use according
intravenous infusion
administered
cationic liposome
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019536978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504138A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/071312 external-priority patent/WO2018127082A1/en
Publication of JP2020504138A publication Critical patent/JP2020504138A/ja
Publication of JP2020504138A5 publication Critical patent/JP2020504138A5/ja
Priority to JP2022146962A priority Critical patent/JP2022180464A/ja
Pending legal-status Critical Current

Links

JP2019536978A 2017-01-05 2018-01-04 膵癌の治療 Pending JP2020504138A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022146962A JP2022180464A (ja) 2017-01-05 2022-09-15 膵癌の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762442636P 2017-01-05 2017-01-05
US62/442,636 2017-01-05
PCT/CN2018/071312 WO2018127082A1 (en) 2017-01-05 2018-01-04 Treatment of pancreatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022146962A Division JP2022180464A (ja) 2017-01-05 2022-09-15 膵癌の治療

Publications (2)

Publication Number Publication Date
JP2020504138A JP2020504138A (ja) 2020-02-06
JP2020504138A5 true JP2020504138A5 (cg-RX-API-DMAC7.html) 2021-02-18

Family

ID=62789060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019536978A Pending JP2020504138A (ja) 2017-01-05 2018-01-04 膵癌の治療
JP2022146962A Pending JP2022180464A (ja) 2017-01-05 2022-09-15 膵癌の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022146962A Pending JP2022180464A (ja) 2017-01-05 2022-09-15 膵癌の治療

Country Status (12)

Country Link
US (2) US20190380994A1 (cg-RX-API-DMAC7.html)
EP (1) EP3565530B1 (cg-RX-API-DMAC7.html)
JP (2) JP2020504138A (cg-RX-API-DMAC7.html)
KR (2) KR20190103304A (cg-RX-API-DMAC7.html)
CN (1) CN110267650A (cg-RX-API-DMAC7.html)
AU (1) AU2018205544B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019013983A2 (cg-RX-API-DMAC7.html)
CA (1) CA3049183A1 (cg-RX-API-DMAC7.html)
IL (1) IL267613B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019008132A (cg-RX-API-DMAC7.html)
TW (1) TWI852903B (cg-RX-API-DMAC7.html)
WO (1) WO2018127082A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
EP4659741A1 (en) * 2023-01-31 2025-12-10 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of paclitaxel cationic liposome in treating tumors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW197439B (cg-RX-API-DMAC7.html) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
AU4242993A (en) 1992-05-21 1993-12-13 Penn State Research Foundation, The Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
ES2331791T5 (es) 2002-06-26 2016-01-21 Medigene Ag Método de producción de una preparación catiónica de liposomas que comprende un compuesto lipófilo
WO2005039533A1 (en) * 2003-10-15 2005-05-06 Medigene Ag Method of administering cationic liposomes comprising an active drug
CA2601067A1 (en) * 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
CA2646156C (en) * 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
CN102946880A (zh) * 2010-04-23 2013-02-27 尼基制药公司 治疗胰腺癌的方法
TWI760319B (zh) * 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
AU2017324947A1 (en) * 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same

Similar Documents

Publication Publication Date Title
AU2023304925B2 (en) Lipid nanoparticles using cationic cholesterol for local delivery for nucleic acid delivery
ES2574231T3 (es) Uso de liposomas catiónicos que comprenden paclitaxel
JP2011507534A5 (cg-RX-API-DMAC7.html)
US9913907B2 (en) RNAi pharmaceutical composition for suppressing expression of KRAS gene
CA3215957A1 (en) Tissue-specific nucleic acid delivery by mixed cationic lipid particles
EP1553923B1 (en) Camptothecin-carboxylate formulations
JP5700909B2 (ja) パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
JP2022180464A (ja) 膵癌の治療
AU2007257357A1 (en) Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
EP1817005A1 (en) Method for loading multiple agents into delivery vehicles
CN104548130A (zh) 一种干扰Claudin3 基因表达的靶向脂质体
JPWO2017111172A1 (ja) カチオン性脂質としての化合物
HK40117407A (en) Lipid nanoparticles using cationic cholesterol for local delivery for nucleic acid delivery
CN104548129A (zh) 一种叶酸受体靶向的干扰Claudin3 基因表达的药物组合物